Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 23:15:1342455.
doi: 10.3389/fimmu.2024.1342455. eCollection 2024.

Targeting latent viral infection in EBV-associated lymphomas

Isabella Y Kong  1 , Lisa Giulino-Roth  1
Affiliations
Review

Targeting latent viral infection in EBV-associated lymphomas

Isabella Y Kong et al. Front Immunol. .

Abstract

Epstein-Barr virus (EBV) contributes to the development of a significant subset of human lymphomas. As a herpes virus, EBV can transition between a lytic state which is required to establish infection and a latent state where a limited number of viral antigens are expressed which allows infected cells to escape immune surveillance. Three broad latency programs have been described which are defined by the expression of viral proteins RNA, with latency I being the most restrictive expressing only EBV nuclear antigen 1 (EBNA1) and EBV-encoded small RNAs (EBERs) and latency III expressing the full panel of latent viral genes including the latent membrane proteins 1 and 2 (LMP1/2), and EBNA 2, 3, and leader protein (LP) which induce a robust T-cell response. The therapeutic use of EBV-specific T-cells has advanced the treatment of EBV-associated lymphoma, however this approach is only effective against EBV-associated lymphomas that express the latency II or III program. Latency I tumors such as Burkitt lymphoma (BL) and a subset of diffuse large B-cell lymphomas (DLBCL) evade the host immune response to EBV and are resistant to EBV-specific T-cell therapies. Thus, strategies for inducing a switch from the latency I to the latency II or III program in EBV+ tumors are being investigated as mechanisms to sensitize tumors to T-cell mediated killing. Here, we review what is known about the establishment and regulation of latency in EBV infected B-cells, the role of EBV-specific T-cells in lymphoma, and strategies to convert latency I tumors to latency II/III.

Keywords: EBNA2; EBNA3; LMP1; T-cell; ebv; latency; lymphoma.

PubMed Disclaimer

Conflict of interest statement

LG-R: consultant for Merck, Roche; research funds from Seagen. The remaining author declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Figures

Figure 1
Figure 1
EBV latency programs. This figure depicts the progression of EBV latency gene expression form initial infection to latency I, from left to right. The EBV genome is illustrated in episomal form closed at the terminal repeats (marked by gray boxes). Promoters are shown as blue boxes, including EBNA (Cp, Wp and Qp) and LMP promoters. Coding regions of transcripts are shown as red boxes (EBNAs) and yellow boxes (LMPs). The list of viral genes expressed in each latency state is shown in bar charts below the diagram.
Figure 2
Figure 2
Latency state of different EBV-associated malignancies. This figure depicts latency programs found in different tumors (, –23). The tumors expressing each latency program are listed below.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Anwar N, Kingma DW, Bloch AR, Mourad M, Raffeld M, Franklin J, et al. . The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt’s lymphoma from Egypt: epidemiologic correlations. Cancer. (1995) 76:1245–52. doi: 10.1002/1097-0142(19951001)76:7<1245::aid-cncr2820760723>3.0.co;2-d - DOI - PubMed
    1. Klumb CE, Hassan R, De Oliveira DE, De Resende LM, Carrico MK, De Almeida Dobbin J, et al. . Geographic variation in Epstein-Barr virus-associated Burkitt’s lymphoma in children from Brazil. Int J Cancer. (2004) 108:66–70. doi: 10.1002/ijc.11443. - DOI - PubMed
    1. Massini G, Siemer D, Hohaus S. EBV in hodgkin lymphoma. Mediterr J Hematol Infect Dis. (2009) 1:e2009013. doi: 10.4084/mjhid. - DOI - PMC - PubMed
    1. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol. (1992) 140:769–74. - PMC - PubMed
    1. Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. (2017) 372(1732). doi: 10.1098/rstb.2016.0270. - DOI - PMC - PubMed

Publication types